ArticleFrontiers in pharmacology2022
Susceptibility of
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Andrographolide as a Promising Diterpenoid Scaffold Against the Neurotropic NematodePharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Probing Cinnamamides and Benzamides as Anthelmintics: Discovery of Potent Drug-Like Agents Against Angiostrongylus cantonensis.Chemical biology & drug design · 2026Article
- Spathulenol, a Sesquiterpene fromACS omega · 2026Article
- Piplartine as an Innovative Natural Product With Dual Antiparasitic and Immunomodulatory Actions.Journal of immunology research · 2026Review
- Structural Exploitation of Cinnarizine Identified Novel Drug-Like Anthelmintic Agents AgainstACS infectious diseases · 2025Article
- Anthelmintic activity of 1,10-phenanthroline-5,6-dione-based metallodrugs.Scientific reports · 2025Article
- Antihistamines HACS omega · 2024Article
- The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs.Future medicinal chemistry · 2024Article
- Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds.Scientific reports · 2023Article
- Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated fromACS omega · 2023Article
- The Existing Drug Nifuroxazide as an Antischistosomal Agent:Microbiology spectrum · 2023Article
- Management of Rat Lungworm Disease (Neuroangiostrongyliasis) Using Anthelmintics: Recent Updates and Recommendations.Pathogens (Basel, Switzerland) · 2022Article
- Neolignans isolated from Saururus cernuus L. (Saururaceae) exhibit efficacy against Schistosoma mansoni.Scientific reports · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human helminthiasis affects approximately one in five people in the world and disproportionally affects the poorest and most deprived communities. Human angiostrongyliasis, caused by nematode
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.